Neuronetics
Manufacturing medical devices for psychiatric and neurological disorders.
Launch date
Employees
Market cap
€20.1m
Enterprise valuation
€38m (Public information from Sep 2024)
Share price
$0.947 STIM
Malvern Iowa (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 49.2m | 55.3m | 65.2m | 71.3m | 77.9m | 87.4m | 99.9m |
| % growth | (21 %) | 12 % | 18 % | 9 % | 9 % | 12 % | 14 % |
| EBITDA | (21.1m) | (26.1m) | (31.3m) | (23.4m) | (11.0m) | (3.2m) | 3.5m |
| % EBITDA margin | (43 %) | (47 %) | (48 %) | (33 %) | (14 %) | (4 %) | 4 % |
| Profit | (27.5m) | (31.2m) | (37.2m) | (30.2m) | (26.7m) | (20.1m) | (14.3m) |
| % profit margin | (56 %) | (56 %) | (57 %) | (42 %) | (34 %) | (23 %) | (14 %) |
| EV / revenue | 4.3x | 2.1x | 2.9x | 1.2x | 0.3x | 0.3x | 0.3x |
| EV / EBITDA | -10.0x | -4.5x | -6.0x | -3.6x | -2.4x | -8.4x | 7.6x |
| R&D budget | 9.2m | 7.9m | 9.3m | 9.5m | - | - | - |
| R&D % of revenue | 19 % | 14 % | 14 % | 13 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | $15.0m | Series A | |
N/A | Seed | ||
$8.5m | Series B | ||
$8.5m | Series B | ||
| N/A | $35.0m | Series C | |
| N/A | $30.0m | Series D | |
$30.0m | Series E | ||
$34.3m | Series F | ||
$15.0m | Series G | ||
| N/A | N/A | IPO | |
* | $50.0m | Post IPO Debt | |
* | N/A | $80.6m | Post IPO Equity |
* | $29.1m | Post IPO Equity | |
* | $60.0m | Post IPO Debt | |
* | $22.5m | Post IPO Debt | |
* | $90.0m | Post IPO Debt | |
| Total Funding | €160m | ||
Recent News about Neuronetics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Neuronetics
Edit
ACQUISITION by Neuronetics Aug 2024